Share:

Years and Volumes

Most Recent Comments

I am not able to find the file with supplementary methods of the present paper. Can somebody help me to find it ?
Thanks
i could not find the supplementary data for this paper. please help me find them. thank you
This paper received over 100,000 hits in the first week it was up!
Success! Thank you for subscribing to receive email notifications when new articles are published in Molecular Medicine 2015. Click here to manage your subscriptions.

 

Articles from this Volume

Letter to the Editor

Karla C Queiroz and C Arnold Spek

 

View article PDF
Posted by Leah Caracappa on Nov 2, 2011 12:00 AM CDT
Letters to the Editor

Julia E Gambone, A Phillip Owens III, and Nigel Mackman

View article PDF

 

Posted by Leah Caracappa on Nov 1, 2011 12:00 AM CDT
Karla C S Queiroz, Cornelis van 't Veer, Yascha van den Berg, JanWillem Duitman, Henri H Versteeg, Hella L Aberson, Angelique P Groot, Marleen I Verstege, Joris J T H Roelofs, Anje A te Velde, and C Arnold Spek

Inflammatory bowel diseases are chronic disorders of the gastrointestinal tract which generally lead to mucosal disruption and ulceration. The etiology and pathogenesis of these diseases remain only moderately understood. Tissue factor (TF) traditionally initiates blood coagulation, but also serves an important role in the body's inflammatory process. Considering the pivotal role of coagulation in inflammatory bowel disease, Queiroz et al. assessed whether genetic ablation of TF might limit experimental colitis. Genetic ablation reduced colitis severity and data suggest TF plays a detrimental role in experimental colitis via enhancement of granulocyte migration into the colon. This process may have pivotal relevance in the clinical setting of inflammatory bowel disease.

View article PDF

 

Posted by Leah Caracappa on Oct 14, 2011 12:00 AM CDT
Noemí Fabelo, Virginia Martín, Gabriel Santpere, Raquel Marín, Laia Torrent, Isidre Ferrer, and Mario Díaz

Parkinson's disease (PD) is a multisystemic, neurodegenerative disease. Classical PD is manifested as a complex motor disorder, while incidental PD (iPD) does not show motor symptoms, and is usually discovered post-mortem. Lipid rafts are microdomains that provide a microenvironment to promote protein-lipid and protein-protein interactions. Recent evidence has demonstrated molecular alterations in PD contribute to abnormal levels of fatty acids in the frontal cortex. Whether altered lipid composition affects highly specialized structures such as lipid rafts is not known. Fabelo et al. purified lipid rafts from the human frontal cortex of normal, early motor stages of PD and iPD subjects and analyzed the lipid composition. The data point to modification of fatty acid contents in polar lipids from lipid rafts in PD and iPD, and indicate these lipid raft abnormalities occur at early stages of PD pathology. Such physicochemical alterations could have a profound impact in lipid raft thermodynamic properties, spatial organization and signal transduction.

View article PDF

 

Posted by Leah Caracappa on Oct 13, 2011 12:00 AM CDT
Sae-Won Lee, Joo-Yun Won, Hae-Young Lee, Ho-Jae Lee, Seock-Won Youn, Ji-Young Lee, Chung-Hyun Cho, Hyun-Jai Cho, Seil Oh, In-Ho Chae, and Hyo-Soo Kim

Prolonged periods of myocardial ischemia may lead to irreversible cardiomyocyte and vasculature loss, which can disrupt cardiac integrity and function. Early reperfusion is the dominant clinical strategy for myocardial salvage. Unfortunately, while early reperfusion is essential for tissue salvage, it also causes myocardial and vascular injury. Angopoietin-1 is an endothelial-specific angiogenic factor known to regulate vessel formation and maintenance of endothelial integrity. The possible effect of angiopoietin-1 on cardiomyocytes and vascular cells during reperfusion has not yet been investigated. To test the protective mechanism of angiopoietin-1, Lee et al. employed a model of myocardial ischemia/reperfusion. The authors show angiopoietin-1 promotes both endothelial integrity and cardiomyocyte survival. The data suggest angopoietin-1 is a prospective therapeutic candidate to preserve myocardial function after reperfusion injury.

View article PDF
S
upplementary data PDF
Posted by Leah Caracappa on Oct 12, 2011 12:00 AM CDT
Fahim Atif, Iqbal Sayeed, Seema Yousuf, Tauheed Ishrat, Fang Hua, Jun Wang, Daniel J Brat, and Donald G Stein

Neuroblastoma is the most common tumor among children under one year, accounting for about 28% of all cancers diagnosed in European and US infants. A safe and effective drug without the adverse side effects associated with radiation or chemotherapy has not yet been found. Studies suggest that progesterone (P4) may have selectively toxic effects. Atif et al. investigated the antitumorogenic effects of P4 in a human neuroblastoma cell line and in a xenograft model of neuroblastoma. Their work showed that at high doses, P4 significantly decreased cell viability and did not induce cell death in healthy primary cortical neurons or human fibroblasts. These results indicate that at high doses, P4 effectively inhibits the growth of solid neuroblastoma tumors while having selective toxicity and a high margin of safety. This suggests P4 may be a possible candidate for clinical treatment of neuroblastoma.

View article PDF

 

Posted by Leah Caracappa on Oct 11, 2011 12:00 AM CDT
Wayne W Chaung, Rongqian Wu, Youxin Ji, Zhimin Wang, Weifeng Dong, Cletus Cheyuo, Lei Qi, Xiaoling Qiang, Haichao Wang, and Ping Wang

Stroke is one of the foremost causes of death in the world and the main cause of acquired adult disability worldwide. Brain injury after acute stroke is mediated in part by ischemia-elicited inflammatory responses. Adrenomedullin (AM), a vasoactive hormone, counterbalances inflammatory responses, however, regulation of AM activity in ischemic stroke remains largely unexplored. Chaung et al. used a model of focal cerebral ischemia, induced by permanent middle cerebral artery occlusion, to investigate the possible benefits of AM. The authors found plasma levels of AM increased significantly after stroke, while plasma levels of AM binding protein (AMBP-1) decreased. Additional treatment with AM and AMBP-1 reduced neuron apoptosis and morphological damage. The data indicate human AM/AMBP-1 could be used to reduce stroke-induced brain injury and may warrant further development.

View article PDF

 

Posted by Leah Caracappa on Oct 10, 2011 12:00 AM CDT
Yi-Chu Liao, Yung-Song Wang, Yuh-Cherng Guo, Kouichi Ozaki, Toshihiro Tanaka, Hsiu-Fen Lin, Ming-Hong Chang, Ku-Chung Chen, Ming-Lung Yu, Sheng-Hsiung Sheu, and Suh-Hang Hank Juo

Ultrasound measurements of intima-media thickness and plaque at the carotid arteries are predictors of future cardiovascular risks, including myocardial infarction (MI) and atherosclerosis. However, these two phenotypes represent distinct traits with unique relationships to atherosclerosis. The BRCA-1 associated protein gene (BRAP) was recently identified as a susceptibility gene for myocardial infarction. In this study, Liao et al. studied the association between BRAP polymorphism and carotid atherosclerosis as well as the mechanism beneath the pro-atherogenic effect. They studied the single nucleotide polymorphism (SNP) rs11066001 because it has been shown to correlate most strongly with MI risks. Inflammatory stimuli up-regulated BRAP expression, while BRAP activated the inflammatory cascades by regulating the NF-ĸB nuclear translocation. These results indicate that the SNP in BRAP confers a risk for carotid atherosclerosis. This work could aid further studies to identify treatment strategies for individuals at risk of atherosclerosis.

View article PDF
Supplemental Data

 

Posted by Leah Caracappa on Oct 9, 2011 12:00 AM CDT
Oleg Bogachev, Amin Majdalawieh, Xuefang Pan, Lei Zhang, and Hyo-Sung Ro

Atherosclerosis is a lethal disease known to be responsible for over half of all reported deaths in the developed world. This is brought about by atherogenesis, a long-term process involving both inflammatory responses and metabolic dysfunction. Two key events in atherogenesis are foam cell formation and macrophage inflammatory response. Adipocyte enhancer-binding protein 1 (AEBP1) has been shown to impede macrophage cholesterol efflux promoting foam cell formation. Bogachev et al. ran a series of experiments using AEBP1-transgenic and AEBP1 knockout mice models, with macrophage-specific AEBP1 overexpression and ablation. The authors' in vivo experimental data suggest that macrophage AEBP1 plays an important regulatory role in the process of atherogenesis, implying that AEBP1 may be a molecular candidate in the development of therapeutic strategies to ameliorate atherosclerosis.

View article PDF 

Supplementary Data

Posted by Leah Caracappa on Oct 8, 2011 12:00 AM CDT
Reinhold J Medina, Christina L O'Neill, T Michelle O'Doherty, Henry Knott, Jasenka Guduric-Fuchs, Tom A Gardiner, and Alan W Stitt

Endothelial progenitor cells (EPCs) promote angiogenesis and may be feasible tools for treating ischaemic disease. Studies have shown one subtype of EPCs, myeloid angiogenic cells (MACs), to be monocytic cells without endothelial characteristics. Medina et al. studied molecular mechanisms to determine whether these cells could be linked to alternative M2 macrophages. Transcriptomic and immunophenotypic analysis found that MACs express typical M2 markers and indicated MACs as an alternative to M2 macrophages. These results suggest that MACs are capable of promoting repair and limiting tissue injury. In the context of ischaemic injury, the authors showed that intra-vitreal delivery of MACs into the ischaemic eye can effectively promote retinal vascular repair and reperfusion. These results could aid in the development of MAC based therapeutic tools for treatment of ischaemia.

View article PDF

Supplemental Data
Supplemental Video

Posted by Leah Caracappa on Oct 7, 2011 12:00 AM CDT
   1 2 3 4 5 6 7 8 9 ... 16